Constraints And Solutions For Biopharmaceutical Manufacturing
By Scott Merz, Sales Manager – The Americas
Biopharmaceutical manufacturing is facing capacity bottlenecks due to process development, downstream chromatography, and equipment constraints. Delays in process development can lead to market competition, resource burdens, and outdated technology. Downstream processing, particularly chromatography, is a bottleneck due to complexity and resource requirements, and equipment constraints and maintenance issues also impact capacity. High costs and limited adaptability hinder scaling up production.
Solutions such as parallel development, advanced software, and AI can increase capacity and streamline processes. Investing in automation and robotics can improve efficiency and product quality. Standardization, modular designs, and reliable suppliers can enhance flexibility and consistency. Predictive maintenance strategies can prevent unexpected downtime. Addressing these bottlenecks is crucial for a consistent supply of life-saving therapies.
This article dives into more detail on the reasons for critical capacity bottlenecks and the challenges and potential solutions associated with each.
Get unlimited access to:
Enter your credentials below to log in. Not yet a member of Bioprocess Online? Subscribe today.